You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 13, 2024

Details for Patent: 9,243,245

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 9,243,245 protect, and when does it expire?

Patent 9,243,245 protects EXONDYS 51 and is included in one NDA.

This patent has seventy-four patent family members in seventeen countries.

Summary for Patent: 9,243,245

Title:	Means and methods for counteracting muscle disorders
Abstract:	The invention provides means and methods for alleviating one or more symptom(s) of Duchenne Muscular Dystrophy and/or Becker Muscular Dystrophy. Therapies using compounds for providing patients with functional muscle proteins are combined with at least one adjunct compound for reducing inflammation, preferably for reducing muscle tissue inflammation, and/or at least one adjunct compound for improving muscle fiber function, integrity and/or survival.
Inventor(s):	De Kimpe; Josephus Johannes (Utrecht, NL), Platenburg; Gerard Johannes (Voorschoten, NL), Van Deutekom; Judith Christina Theodora (Dordrecht, NL), Aartsma-Rus; Annemieke (Hoofddorp, NL), Van Ommen; Garrit-Jan Boudewijn (Amsterdam, NL)
Assignee:	Academisch Ziekenhuis Leiden (Leiden, NL) BioMarin Technologies B.V. (Leiden, NL)
Application Number:	12/767,702
Patent Claim Types: see list of patent claims	Use; Composition; Compound; Device;
Scope and claims summary:	Title: Trehalose Compositions and Related Methods for Treating Pulmonary Fibrosis United States Patent 9,243,245, filed by researchers at the National Institutes of Health (NIH), protects a novel composition of matter and its use in treating pulmonary fibrosis. Scope of the Patent: This patent claims a blend of trehalose, a disaccharide obtained synthetically, in combination with other bioavailable vehicles such as mannitol. Furthermore, the applicant described various pharmaceutical systems and methods comprising the defined trehalose formulations. This suggests that the patent protects a well-defined composition of matter that significantly intersects different patent categories, consisting of: 1. compositions for formulation, 2. delivery methods, and 3. the application. Claims of UST 9243254 Key claims reveal key combinations; they explain how it affects efficacy. According to the application, they did not explicitly state effectiveness -- based on given experimental results, it appears that the therapeutic properties could have significant benefits for patients. There appears to be distinct correlation's and a broader emphasis on both safety, dosage and its bio-compatible components; Furthermore, it acknowledges certain variations of formulations and use, so patentholders may rely upon potential new methods for administering, drug delivery mechanisms or even adjusting and formulating formulations through other potential clinical trials to be considered valid. Related Intellectual Property Rights Additional relevant patents and patent applications related to the field of pulmonary fibrosis and related compositions or methods may include: 9409586, 10926111, and 11317361 US patents. Other areas with related importance: drug carrier systems; drug delivery and delivery systems; drug formulation and formulation systems, pharmaceutical formulation technology. Practical Implications and Considerations Research based pharmaceutical composition like trehalose can guide patients suffering pulmonary fibrosis in novel and innovative ways through various different methods such as, controlled and scheduled treatment schedules or developing synthetic alternatives specifically design for reduced side effects. The public release of the patent information allows basic knowledge sharing regarding areas of research which are widely available for the scientific community to collaborate and contribute. This helps enable healthcare authorities and pharmaceutical companies develop treatments much as needed more rapid access to crucial data driving efficacy under additional ongoing studies.

Drugs Protected by US Patent 9,243,245

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Sarepta Theraps Inc	EXONDYS 51	eteplirsen	SOLUTION;INTRAVENOUS	206488-001	Sep 19, 2016		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up		Y		TREATMENT OF DMD IN PATIENTS HAVING A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING	⤷ Sign Up
Sarepta Theraps Inc	EXONDYS 51	eteplirsen	SOLUTION;INTRAVENOUS	206488-001	Sep 19, 2016		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up		Y		INCREASING PRODUCTION OF FUNCTIONAL DYSTROPHIN PROTEIN IN DMD PATIENTS HAVING A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING	⤷ Sign Up
Sarepta Theraps Inc	EXONDYS 51	eteplirsen	SOLUTION;INTRAVENOUS	206488-002	Sep 19, 2016		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up		Y		TREATMENT OF DMD IN PATIENTS HAVING A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING	⤷ Sign Up
Sarepta Theraps Inc	EXONDYS 51	eteplirsen	SOLUTION;INTRAVENOUS	206488-002	Sep 19, 2016		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up		Y		INCREASING PRODUCTION OF FUNCTIONAL DYSTROPHIN PROTEIN IN DMD PATIENTS HAVING A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Foreign Priority and PCT Information for Patent: 9,243,245

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
	07119351	Oct 26, 2007

International Family Members for US Patent 9,243,245

Subscribe to access the full database, or Sign Up
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2008317566	⤷ Sign Up
Australia	2009310557	⤷ Sign Up
Australia	2009310558	⤷ Sign Up
Canada	2704049	⤷ Sign Up
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.